On March 31, 2021, Liu, Juan; Zhang, Yuan; Huang, Honglin; Lei, Xiaoyong; Tang, Guotao; Cao, Xuan; Peng, Junmei published an article.COA of Formula: C26H29Cl2N5O3 The title of the article was Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. And the article contained the following:
A review. BCR-ABL is a gene produced by the fusion of the bcr gene and the c-abl proto-oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production Therefore, the development of selective Bcr-Abl kinase inhibitors is an attractive strategy for the treatment of CML. However, in the treatment of CML with a Bcr-Abl kinase inhibitor, the T315I gatekeeper mutant disrupts the important contact interaction between the inhibitor and the enzyme, resistant to the first- and second-generation drugs currently approved, such as imatinib, bosutinib, nilotinib, and dasatinib. In order to overcome this special resistance, several different strategies have been explored, and many mols. have been studied to effectively inhibit Bcr-Abl T315I. Some of these mols. are still under development, and some are being studied preclinically, and still others are in clin. research. Herein, this review reports some of the major examples of third-generation Bcr-Abl inhibitors against the T315I mutation. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3
The Article related to review imatinib bosutinib anticancer bcr abl chronic myelogenous leukemia, atp-competitive inhibitors, bcr-abl, t315i mutation, chronic myelogenous leukemia, non-atp-competitive inhibitors and other aspects.COA of Formula: C26H29Cl2N5O3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics